Investment Thesis
GridAI Technologies faces existential financial challenges as a pharmaceutical company with only $38.2K in quarterly revenue while incurring $3.6M in operating losses and burning $1.8M in operating cash. The company is in acute liquidity distress with a current ratio of 0.16x and merely $385.5K in cash reserves, making immediate solvency highly questionable without emergency capital infusion. The fundamental business model is non-functional with negative margins exceeding -9,400% across all profitability metrics.
Strengths
- Positive stockholders equity base of $23.6M provides some residual asset cushion
- Moderate leverage with debt-to-equity ratio of 0.27x and manageable long-term debt of $6.4M
- Marginal YoY improvement in net loss and EPS metrics suggest potential cost reduction efforts
Risks
- Critical liquidity crisis with current ratio of 0.16x and only $385.5K cash against operating burn of $1.8M quarterly
- Unsustainable operating model with $3.6M quarterly losses on $38.2K revenue indicating complete disconnect between costs and commercialization
- Pharmaceutical company with no revenue traction despite operating expenses suggesting product failure or pre-commercialization stage with dwindling runway
Key Metrics to Watch
- Quarterly cash position and burn rate sustainability against runway to next funding milestone
- Revenue generation momentum and evidence of product commercialization
- Secured capital raises or strategic alternatives announcements
Financial Metrics
Revenue
38.2K
Net Income
-3.6M
EPS (Diluted)
$-0.82
Free Cash Flow
-1.9M
Total Assets
48.0M
Cash
385.5K
Profitability Ratios
Gross Margin
-1,606.3%
Operating Margin
-9,460.1%
Net Margin
-9,510.3%
ROE
-15.4%
ROA
-7.6%
FCF Margin
-4,858.2%
Balance Sheet & Liquidity
Current Ratio
0.16x
Quick Ratio
0.16x
Debt/Equity
0.27x
Debt/Assets
42.7%
Interest Coverage
-54.60x
Long-term Debt
6.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-28T07:35:56.746674 |
Data as of: 2026-03-31 |
Powered by Claude AI